Real-time monitoring of enzyme-catalyzed phosphoribosylation of anti-influenza prodrug favipiravir by time-lapse nuclear magnetic resonance spectroscopy.
Aciclovir, Avigan
HGPRT
RNA-genome viruses
SARS-CoV-2
SBDD
fluorine-19
phosphorus-31
Journal
NMR in biomedicine
ISSN: 1099-1492
Titre abrégé: NMR Biomed
Pays: England
ID NLM: 8915233
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
01
12
2022
received:
10
06
2022
accepted:
02
12
2022
medline:
17
4
2023
pubmed:
6
12
2022
entrez:
5
12
2022
Statut:
ppublish
Résumé
Favipiravir (brand name Avigan), a widely known anti-influenza prodrug, is metabolized by endogenous enzymes of host cells to generate the active form, which exerts inhibition of viral RNA-dependent RNA polymerase activity; first, favipiravir is converted to its phosphoribosylated form, favipiravir-ribofuranosyl-5'-monophosphate (favipiravir-RMP), by hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Because this phosphoribosylation reaction is the rate-determining step in the generation of the active metabolite, quantitative and real-time monitoring of the HGPRT-catalyzed reaction is essential to understanding the pharmacokinetics of favipiravir. However, assay methods enabling such monitoring have not been established.
Substances chimiques
favipiravir
EW5GL2X7E0
Prodrugs
0
Hypoxanthine Phosphoribosyltransferase
EC 2.4.2.8
Amides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4888Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363(6428):418-423. doi:10.1038/363418a0
Kim CU, Lew W, Williams MA, et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem. 1998;41(14):2451-2460. doi:10.1021/jm980162u
Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell. 1992;69(3):517-528. doi:10.1016/0092-8674(92)90452-i
Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67(9):5585-5594. doi:10.1128/JVI.67.9.5585-5594.1993
Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977-981. doi:10.1128/AAC.46.4.977-981.2002
Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981-986. doi:10.1128/AAC.49.3.981-986.2005
Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102. doi:10.1016/j.antiviral.2009.02.198
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446-454. doi:10.1016/j.antiviral.2013.09.015
Peng Q, Peng R, Yuan B, et al. Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir. Innovations. 2021;2(1):100080. doi:10.1016/j.xinn.2021.100080
Naydenova K, Muir KW, Wu LF, et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc Natl Acad Sci U S A. 2021;118(7):e2021946118. doi:10.1073/pnas.2021946118
Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010;54(6):2517-2524. doi:10.1128/AAC.01739-09
Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 2010;107(2):882-887. doi:10.1073/pnas.0909603107
Naesens L, Guddat LW, Keough DT, et al. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 2013;84(4):615-629. doi:10.1124/mol.113.087247
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. doi:10.1016/j.pharmthera.2020.107512
Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746. doi:10.1038/s41594-021-00651-0
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1):100770. doi:10.1016/j.jbc.2021.100770
Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021;12(1):279. doi:10.1038/s41467-020-20542-0
Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020;117(43):26955-26965. doi:10.1073/pnas.2014441117
Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. doi:10.1038/s41598-021-90551-6
Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther. 2021;10(4):2489-2509. doi:10.1007/s40121-021-00517-4
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489. doi:10.1186/s12879-021-06164-x
Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501-508. doi:10.1016/j.ijid.2020.10.069
Sugiki T, Furuita K, Fujiwara T, Kojima C. Current NMR techniques for structure-based drug discovery. Molecules. 2018;23(1):148. doi:10.3390/molecules23010148
Cantrelle FX, Boll E, Brier L, et al. NMR spectroscopy of the main protease of SARS-CoV-2 and fragment-based screening identify three protein hotspots and an antiviral fragment. Angew Chem Int Ed Engl. 2021;60(48):25428-25435. doi:10.1002/anie.202109965
Boeszoermenyi A, Chhabra S, Dubey A, et al. Aromatic 19F-13C TROSY: a background-free approach to probe biomolecular structure, function, and dynamics. Nat Methods. 2019;16(4):333-340. doi:10.1038/s41592-019-0334-x
Bann JG, Pinkner J, Hultgren SJ, Frieden C. Real-time and equilibrium (19)F-NMR studies reveal the role of domain-domain interactions in the folding of the chaperone PapD. Proc Natl Acad Sci U S A. 2002;99(2):709-714. doi:10.1073/pnas.022649599
Mashiach R, Weissman H, Avram L, et al. In situ NMR reveals real-time nanocrystal growth evolution via monomer-attachment or particle-coalescence. Nat Commun. 2021;12(1):229. doi:10.1038/s41467-020-20512-6
Nguyen TTM, Mai VH, Kim HS, et al. Real-time monitoring of host-gut microbial interspecies interaction in anticancer drug metabolism. J Am Chem Soc. 2022;144(19):8529-8535. doi:10.1021/jacs.1c10998
Takahashi R, Nakamura S, Nakazawa T, et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem. 2010;147(1):95-107. doi:10.1093/jb/mvp152
Escobedo-Hinojosa W, Wissner JL, Hauer B. A real-time (31)P-NMR-based approach for the assessment of glycerol kinase catalyzed monophosphorylations. MethodsX. 2021;8:101285. doi:10.1016/j.mex.2021.101285
Van QN, Shaka AJ. Improved cross peak detection in two-dimensional proton NMR spectra using excitation sculpting. J Magn Reson. 1998;132(1):154-158. doi:10.1006/jmre.1998.1404
Olp MD, Kalous KS, Smith BC. ICEKAT: an interactive online tool for calculating initial rates from continuous enzyme kinetic traces. BMC Bioinformatics. 2020;21(1):186. doi:10.1186/s12859-020-3513-y
Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6(3):277-293. doi:10.1007/BF00197809
Lee W, Tonelli M, Markley J. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics. 2015;31(8):1325-1327. doi:10.1093/bioinformatics/btu830
Smithers GW, O'Sullivan WJ. 31P nuclear magnetic resonance study of phosphoribosyldiphosphate and its interaction with magnesium ions. J Biol Chem. 1982;257(11):6164-6170.
Juranic N, Nemultu E, Zhang S, Dzeja P, Terzic A, Macura S. (31)P NMR correlation maps of (18)O/ (16)O chemical shift isotopic effects for phosphometabolite labeling studies. J Biomol NMR. 2011;50:237-245.
Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. doi:10.1371/journal.pone.0186459
Achanta PS, Chen SN, Pauli GF. Plain 1H nuclear magnetic resonance analysis streamlines the quality control of antiviral favipiravir and congeneric World Health Organization essential medicines. Magn Reson Chem. 2021;59(7):746-751. doi:10.1002/mrc.5154
Jeong HJ, Min S, Chae H, et al. Signal amplification by reversible exchange for COVID-19 antiviral drug candidates. Sci Rep. 2020;10(1):14290. doi:10.1038/s41598-020-71282-6
Lee Y, Zeng H, Ruedisser S, Gosser A, Hilty C. Nuclear magnetic resonance of hyperpolarized fluorine for characterization of protein-ligand interactions. J Am Chem Soc. 2012;134(42):17448-17451. doi:10.1021/ja308437h
Keshari KR, Wilson DM. Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. Chem Soc Rev. 2014;43(5):1627-1659. doi:10.1039/c3cs60124b
Min H, Sekar G, Hilty C. Polarization transfer from ligands hyperpolarized by dissolution dynamic nuclear polarization for screening in drug discovery. Chem Med Chem. 2015;10(9):1559-1563. doi:10.1002/cmdc.201500241
Wang Y, Hilty C. Determination of ligand binding epitope structures using polarization transfer from hyperpolarized ligands. J Med Chem. 2019;62(5):2419-2427. doi:10.1021/acs.jmedchem.8b01711
Kim Y, Hilty C. Applications of dissolution-DNP for NMR screening. Methods Enzymol. 2019;615:501-526. doi:10.1016/bs.mie.2018.08.016
Negoro M, Kagawa A, Tateishi K, et al. Dissolution dynamic nuclear polarization at room temperature using photoexcited triplet electrons. J Phys Chem A. 2018;122(17):4294-4297. doi:10.1021/acs.jpca.8b01415
Tateishi K, Negoro M, Nonaka H, et al. Dynamic nuclear polarization with photo-excited triplet electrons using 6,13-diphenylpentacene. Phys Chem Chem Phys. 2019;21(36):19737-19741. doi:10.1039/c9cp00977a
Kagawa A, Miyanishi K, Ichijo N, et al. High-field NMR with dissolution triplet-DNP. J Magn Reson. 2019;309:106623. doi:10.1016/j.jmr.2019.106623